Optimizing Decision-Making in CLL in an Era of Novel Agents

A comprehensive educational program featuring expert insight commentaries an Interactive Treatment Decision Support tool and a series of microeducation modules to fortify your practice in managing patients with CLL.

Share

Program Content

Activities

1L: High-Risk Patient
Cases in CLL Slides: High-Risk Patient Requiring First-line Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

1L: Fit Patient
Cases in CLL Slides: Fit, Younger Patient Requiring First-line Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

1L: Older Patient
Cases in CLL Slides: Options for an Older Patient Requiring First-line Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 12, 2020

Expires: October 11, 2021

2L: Post CIT
Cases in CLL Slides: Second-Line Therapy Following Chemoimmunotherapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

2L+: Ibrutinib Intolerance
Cases in CLL Slides: Patient Progressing on BR With Subsequent Ibrutinib Intolerance
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2020

Expires: September 30, 2021

3L: Post BTKi/VenR
Cases in CLL Slides: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

Activities

Ibrutinib + Rituximab
Ibrutinib Plus Rituximab and the Expanding Therapeutic Toolbox for Previously Untreated CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2020

Expires: June 25, 2021

CLL: Expert Perspectives
Expert Perspectives on Key New Evidence in CLL Therapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2021

Expires: July 27, 2022

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner